14,822 reports of this reaction
4.1% of all LEVONORGESTREL reports
#4 most reported adverse reaction
VAGINAL HAEMORRHAGE is the #4 most commonly reported adverse reaction for LEVONORGESTREL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 14,822 FDA adverse event reports linking LEVONORGESTREL to VAGINAL HAEMORRHAGE. This represents approximately 4.1% of all 357,584 adverse event reports for this drug.
Patients taking LEVONORGESTREL who experience vaginal haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VAGINAL HAEMORRHAGE is moderately reported among LEVONORGESTREL users, representing a notable but not dominant share of adverse events.
In addition to vaginal haemorrhage, the following adverse reactions have been reported for LEVONORGESTREL:
The following drugs have also been linked to vaginal haemorrhage in FDA adverse event reports:
VAGINAL HAEMORRHAGE has been reported as an adverse event in 14,822 FDA reports for LEVONORGESTREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
VAGINAL HAEMORRHAGE accounts for approximately 4.1% of all adverse event reports for LEVONORGESTREL, making it a notable side effect.
If you experience vaginal haemorrhage while taking LEVONORGESTREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.